CNTX-4975新薬の考察と市場予測 - 2032年

当レポートでは、CNTX-4975新薬の主要6市場（米国、ドイツ、フランス、イタリア、スペイン、英国）およびカナダ市場、韓国市場について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症におけるCNTX-4975の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 CNTX-4975市場の評価

• 変形性関節症におけるCNTX-4975の市場見通し
• 主要6市場、カナダ、韓国の分析
  • 主要6市場、カナダ、韓国の変形性関節症向けCNTX-4975の市場規模
• 市場の分析：国別
  • 米国の変形性関節症向けCNTX-4975の市場規模
  • ドイツの変形性関節症向けCNTX-4975の市場規模
  • 英国の変形性関節症向けCNTX-4975の市場規模
  • カナダの変形性関節症向けCNTX-4975の市場規模
  • 韓国の変形性関節症向けCNTX-4975の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: CNTX-4975, Clinical Trial Description, 2023
• Table 2: CNTX-4975, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: CNTX-4975 Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: CNTX-4975 Market Size in the US, in USD million (2019-2032)
• Table 7: CNTX-4975 Market Size in Germany, in USD million (2019-2032)
• Table 8: CNTX-4975 Market Size in France, in USD million (2019-2032)
• Table 9: CNTX-4975 Market Size in Italy, in USD million (2019-2032)
• Table 10: CNTX-4975 Market Size in Spain, in USD million (2019-2032)
• Table 11: CNTX-4975 Market Size in the UK, in USD million (2019-2032)
• Table 12: CNTX-4975 Market Size in Canada, in USD million (2019-2032)
• Table 13: CNTX-4975 Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: CNTX-4975 Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: CNTX-4975 Market Size in the United States, USD million (2019-2032)
• Figure 3: CNTX-4975 Market Size in Germany, USD million (2019-2032)
• Figure 4: CNTX-4975 Market Size in France, USD million (2019-2032)
• Figure 5: CNTX-4975 Market Size in Italy, USD million (2019-2032)
• Figure 6: CNTX-4975 Market Size in Spain, USD million (2019-2032)
• Figure 7: CNTX-4975 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: CNTX-4975 Market Size in Canada, USD million (2019-2032)
• Figure 9: CNTX-4975 Market Size in Korea, USD million (2019-2032)

“"CNTX-4975 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CNTX-4975 for osteoarthritis in the six major markets. A detailed picture of the CNTX-4975 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the CNTX-4975 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNTX-4975 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

Centrexion Therapeutics' lead product candidate, CNTX-4975, is being evaluated for the treatment of moderate to severe pain of knee OA. CNTX-4975 is an ultra-pure, synthetic form of trans-capsaicin injected directly into the pain site. It harnesses the natural analgesic power of capsaicin to develop a proprietary injectable therapy designed to provide fast-acting, durable and targeted pain relief.

The TRPV1 receptor that selectively inactivates local pain fibers transmitting pain signals to the brain is targeted by CNTX-4975, potentially providing relief that can last up to 6 months until local pain fibers are regenerated. CNTX-4975 manages pain without disrupting other nerve functions through its targeted delivery and highly-selective method of action.

Additionally, three Phase III clinical trials, namely VICTORY-1, VICTORY-2, and VICTORY-3 studies, are in progress for CNTX-4975 examining capsaicin and its potential to provide extended relief from knee OA. Apart from that, the company is also evaluating the other product CNTX-6970 (CCR2 antagonist) in Phase IIa for OA pain.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CNTX-4975 description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on CNTX-4975 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CNTX-4975 research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around CNTX-4975.
• The report contains forecasted sales of CNTX-4975 for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for CNTX-4975 in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CNTX-4975 Analytical Perspective by DelveInsight

• In-depth CNTX-4975 Market Assessment

This report provides a detailed market assessment of CNTX-4975 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

• CNTX-4975 Clinical Assessment

The report provides the clinical trials information of CNTX-4975 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CNTX-4975 dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to CNTX-4975 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CNTX-4975 in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of CNTX-4975 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CNTX-4975 in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of CNTX-4975?
• What is the clinical trial status of the study related to CNTX-4975 in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CNTX-4975 development?
• What are the key designations that have been granted to CNTX-4975 for osteoarthritis?
• What is the forecasted market scenario of CNTX-4975 for osteoarthritis?
• What are the forecasted sales of CNTX-4975 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to CNTX-4975 for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. CNTX-4975 Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CNTX-4975 Market Assessment

• 5.1. Market Outlook of CNTX-4975 in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of CNTX-4975 in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CNTX-4975 in the United States for Osteoarthritis
  • 5.3.2. Market Size of CNTX-4975 in Germany for Osteoarthritis
  • 5.3.3. Market Size of CNTX-4975 in France for Osteoarthritis
  • 5.3.4. Market Size of CNTX-4975 in Italy for Osteoarthritis
  • 5.3.5. Market Size of CNTX-4975 in Spain for Osteoarthritis
  • 5.3.6. Market Size of CNTX-4975 in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of CNTX-4975 in Canada for Osteoarthritis
  • 5.3.8. Market Size of CNTX-4975 in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options